{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:21:05Z","timestamp":1775841665347,"version":"3.50.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Aquaporin-4 antibodies (AQP4-Abs) are a diagnostic marker for patients with a demyelinating disease called neuromyelitis optica spectrum disorder (NMOSD). Anti-Argonaute antibodies (AGO-Abs) present as potential biomarkers of the overlap syndrome between NMOSD and other autoimmune diseases. In this paper, we present the case of an adult woman with numbness, tingling, and burning sensations in her arms and subsequent bilateral internuclear ophthalmoplegia. Brain\u2013cervical\u2013thoracic magnetic resonance imaging (MRI) showed T2 hyperintensities in the dorsal brainstem and around the midbrain aqueduct and longitudinally transverse myelitis with homogeneous enhancement on gadolinium-enhanced MRI. The contemporaneous detection of AQP4- and AGO-Abs led to a definite diagnosis of overlap syndrome of NMOSD with AGO-Abs. The patient was treated with immunosuppressive agents, including corticosteroids and immunoglobulins, and achieved remission. This case highlights a novel phenotype of NMOSD with AGO-Abs overlap syndrome, which presents with relapsing brainstem syndrome and longitudinally extensive myelitis with acute severe neurological involvement. The promising prognosis of the disease could serve as a distinct clinical profile. Broad screening for antibodies against central nervous system autoimmune antigens is recommended in suspected patients with limited or atypical clinical manifestations.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1366531","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T04:23:48Z","timestamp":1717388628000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case report: Overlap syndrome of neuromyelitis optica spectrum disorder with anti-Argonaute antibodies"],"prefix":"10.3389","volume":"15","author":[{"given":"Pei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songdi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00281\u2013022-00941\u20139","article-title":"Immuno-pathogenesis of neuromyelitis optica and emerging therapies","volume":"44","author":"Chihara","year":"2022","journal-title":"Semin immunopathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00415\u2013023-11634\u20130","article-title":"Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis","volume":"270","author":"Jarius","year":"2023","journal-title":"J Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1186\/1742\u20132094-10\u20138","article-title":"The history of neuromyelitis optica","volume":"10","author":"Jarius","year":"2013","journal-title":"J Neuroinflamm"},{"key":"B5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974\u2013019-1594\u20131","article-title":"The history of neuromyelitis optica. Part 2: \u2018Spinal amaurosis\u2019, or how it all began","volume":"16","author":"Jarius","year":"2019","journal-title":"J Neuroinflamm"},{"key":"B6","doi-asserted-by":"publisher","first-page":"R87","DOI":"10.1186\/ar1959","article-title":"Autoimmune targeting of key components of RNA interference","volume":"8","author":"Jakymiw","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/ar1987","article-title":"The RNA interference pathway: a new target for autoimmunity","volume":"8","author":"Pruijn","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001032","article-title":"Argonaute autoantibodies as biomarkers in autoimmune neurologic diseases","volume":"8","author":"Do","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1006\/clin.1994.1179","article-title":"Characterization of the Su antigen, a macromolecular complex of 100\/102 and 200-kDa proteins recognized by autoantibodies in systemic rheumatic diseases","volume":"73","author":"Satoh","year":"1994","journal-title":"Clin Immunol immunopathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780271108","article-title":"Characterization of a new antigen-antibody system (Su) in patients with systemic lupus erythematosus","volume":"27","author":"Treadwell","year":"1984","journal-title":"Arthritis rheuma"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200105","article-title":"Anti-AGO1 antibodies identify a subset of autoimmune sensory neuronopathy","volume":"10","author":"Moritz","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022\u2013330707","article-title":"Anti-Argonaute antibodies as a potential biomarker in NMOSD","volume":"94","author":"Carta","year":"2023","journal-title":"J neurol neurosurg Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1006-2963.2021.06.002","article-title":"Guidelines for diagnosis and treatment of neuromyelitis spectrum diseases in China (2021)","volume":"28","year":"2021","journal-title":"Chin J Neuroimmunol Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231199819","article-title":"Double-negative neuromyelitis optica spectrum disorder","volume":"29","author":"Wu","year":"2023","journal-title":"Mult Scler"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1212\/NXI.0000000000000225","article-title":"Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus","volume":"3","author":"Sepulveda","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2022.18.4.453","article-title":"Disease course and outcomes in patients with thelimited form of neuromyelitis optica spectrum disorders and negative AQP4-IgG serology at disease onset: a prospective cohort study","volume":"18","author":"Chen","year":"2022","journal-title":"J Clin Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12087","article-title":"Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status","volume":"23","author":"Sato","year":"2013","journal-title":"Brain Pathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00415\u2013023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management","volume":"271","author":"Kumpfel","year":"2023","journal-title":"J Neurol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00296\u2013023-05397\u20130","article-title":"Overlap syndrome of anti-aquaporin 4 positive neuromyelitis optica spectrum disorder and primary Sjogren\u2019s syndrome: a systematic review of individual patient data","author":"Prasad","year":"2023","journal-title":"Rheumatol Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001145","article-title":"The clinical characteristics of primary Sjogren\u2019s syndrome with neuromyelitis optica spectrum disorder in China: a STROBE-compliant article","volume":"94","author":"Qiao","year":"2015","journal-title":"Medicine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.05.005","article-title":"Neuromyelitis optica spectrum disorder as an initial presentation of primary Sjogren\u2019s syndrome","volume":"40","author":"Kahlenberg","year":"2011","journal-title":"Semin Arthritis rheuma"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/1352458509106228","article-title":"Brain abnormalities in Sjogren syndrome with recurrent CNS manifestations: association with neuromyelitis optica","volume":"15","author":"Min","year":"2009","journal-title":"Mult Scler"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/0961203319877255","article-title":"Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder and systemic autoimmune diseases overlap syndrome: a single-center experience","volume":"28","author":"Martin-Nares","year":"2019","journal-title":"Lupus"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.959469","article-title":"The causal relationship between neuromyelitis optica spectrum disorder and other autoimmune diseases","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.972161","article-title":"Conformation-stabilizing ELISA and cell-based assays reveal patient subgroups targeting three different epitopes of AGO1 antibodies","volume":"13","author":"Moritz","year":"2022","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2007.05.001","article-title":"Argonaute proteins: mediators of RNA silencing","volume":"26","author":"Peters","year":"2007","journal-title":"Mol Cell"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2005.10.048","article-title":"Identification of novel argonaute-associated proteins","volume":"15","author":"Meister","year":"2005","journal-title":"Curr biol: CB"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2165\/11631480\u2013000000000\u201300000","article-title":"MicroRNAs in rheumatoid arthritis: potential role in diagnosis and therapy","volume":"26","author":"Filkova","year":"2012","journal-title":"BioDrugs: Clin immunother biopharmaceutic Gene Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2017.06.022","article-title":"Autoantibodies to Su\/Argonaute 2 in Japanese patients with inflammatory myopathy","volume":"471","author":"Ogawa-Momohara","year":"2017","journal-title":"Clinica chimica acta; Int J Clin Chem"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2010.499886","article-title":"Anti-argonaute2 (Ago2\/Su) and -Ro antibodies identified by immunoprecipitation in primary anti-phospholipid syndrome (PAPS)","volume":"44","author":"Ceribelli","year":"2011","journal-title":"Autoimmunity"},{"key":"B31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12974\u2013016-0678\u20134","article-title":"Mapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous system","volume":"13","author":"Sinmaz","year":"2016","journal-title":"J Neuroinflamm"},{"key":"B32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nri724","article-title":"Epitope spreading in immune-mediated diseases: implications for immunotherapy","volume":"2","author":"Vanderlugt","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front Neurol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103494","article-title":"Clinical significance of anti-SSA\/Ro antibody in Neuromyelitis optica spectrum disorders","volume":"58","author":"Lin","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"B35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11926\u2013021-01000\u20132","article-title":"Neuromyelitis optica spectrum disorders (NMOSD) and connective tissue disease (CTD): an update for the rheumatologist","volume":"23","author":"Cruz","year":"2021","journal-title":"Curr Rheumatol Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1366531\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T10:17:41Z","timestamp":1721384261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1366531\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2024.1366531"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1366531","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]},"article-number":"1366531"}}